ImmunoGen — Investor Presentation (January 2020)
23 slides from ImmunoGen's investor presentation, Jan 13, 2020
Slide 1: Target a Better Now: Corporate Presentation
T A R G E T A B E T T E R N O W Nasdaq: IMGN Corporate Presentation As of January 13, 2020 Exhibit 99.1
Slide 2: Forward-Looking Statements
2 FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements regarding ImmunoGen’s expectations related to the design and potential success of ImmunoGen’s future mirvetuximab soravtansine and IMGN632 clinical studies and regulatory pathways, including the timing of initiating a
Slide 3: Why ImmunoGen?
3 WHY IMMUNOGEN? ACCELERATED P A T H T O PIVOTAL DATA IN 2021 AND APPROVAL IN 2022 ROBUST DATA I N L E A D MIRVETUXIMAB PROGRAM STRONG CASH POSITION D I V E R S E PORTFOLIO OF EARLY STAGE P R O D U C T CANDIDATES ANTICIPATED C O M P E N D I A LISTING FOR FOLLOW- O N INDICATIONS BEGINNING I N 2 0 2 2
Slide 4: Strategic Priorities
4 BRINGING ANTIBODY - DRUG CONJUGATES TO CANCER PATIENTS STRATEGIC PRIORITIES F U R T H E R STRENGTHEN BALANCE SHEET AND EXPAND CAPABILITIES T H R O U G H PARTNERSHIPS ADVANCE PORTFOLIO OF EARLY STAGE P R O D U C T CANDIDATES E X E C U T E MIRVETUXIMAB REGISTRATION STUDIES AND PURSUE LABEL EXPANSION
Slide 5: Someone you know has been diagnosed with ovarian cancer
SOMEONE YOU KNOW HAS BEEN DIAGNOSED WITH OVARIAN CANCER … WHAT’S NEXT FOR HER? 5
Slide 6: Urgent Need
U R G E N T NEED 1NIH SEER Data: Estimated New Cases, 2019. 2JCO: Vol 33, No. 32, Nov 2015. 3Gyn Onc 133(2014) 624-631. PFS: progression-free survival; PARPi: poly-ADP ribose polymerase inhibitor; BEV: bevacizumab OVARIAN CANCER IS THE LEADING CAUSE OF DEATH FROM GYNECOLOGICAL CANCERS >14,000 WOMEN
Slide 7: Mirvetuximab Soravtansine
MIRVETUXIMAB SORAVTANSINE 7 DESIGNED TO DISPLACE CHEMOTHERAPY TO DELIVER MORE GOOD DAYS FOR WOMEN WITH OVARIAN CANCER KEY ATTRIBUTES • ADC with distinct FRα target and mechanism of action • Demonstrated activity in patients with platinum-resistant and platinum-sensitive ovarian cancer1 • Well tolera
Slide 8: Aligned with FDA Recommendations
8 ALIGNED WITH FDA RECOMMENDATIONS WOMEN WITH FRα -H I G H PLATINUM-R E S I S T A N T OVARIAN CANCER THAT HAS PROGRESSED AFTER PRIOR TREATMENT WITH BEVACIZUMAB REQUIRE BETTER THERAPEUTIC OPTIONS MIRVETUXIMAB: POTENTIAL FOR ACCELERATED APPROVAL SUPPORTING DATA POOLED POST-HOC ANALYSIS FROM PHASE 1 AN
Slide 9: Single-Arm Pivotal Trial (SORAYA)
9 SINGLE-ARM PIVOTAL TRIAL FOR MIRVETUXIMAB USING PS2+ SCORING IN FRα-HIGH, PLATINUM-RESISTANT OVARIAN CANCER PRIMARY ENDPOINT ORR by Investigator SECONDARY ENDPOINT DOR by Investigator FPI Q1 2020 TARGET TIMELINES ENROLLMENT AND KEY ELIGIBILITY ~100 patients Platinum-resistant disease (primary PFI
Slide 10: Prior Phase Experience: FORWARD I
10 PRIOR PHASE 3 EXPERIENCE FORWARD I DID NOT MEET PRIMARY ENDPOINT GENERATED ROBUST DATA TO INFORM POTENTIAL REGISTRATION PHYSICIAN’S CHOICE OF PACLITAXEL, PLD, OR TOPOTECAN MIRVETUXIMAB 2:1 RANDOMIZATION PRIMARY ENDPOINT PFS for all patients and for FRα-high expressers only ENROLLMENT 366 patients
Slide 11: Applying Lessons Learned from FORWARD I
11 APPLYING LESSONS LEARNED FROM FORWARD I WE BELIEVE THESE DESIGN FACTORS WILL IMPROVE THE PROBABILITY OF TECHNICAL SUCCESS FOR MIRASOL DESIGN FACTOR INSIGHT 11 n=366 n=430 FRα-highs benefited most PS2+ reliably identified patients most likely to benefit Efficient, conservative design Preserves alp
Slide 12: Phase 3 MIRASOL Randomized Trial
12 ENROLLMENT AND KEY ELIGIBILITY • 430 patients/330 events for PFS by Investigator • Platinum-resistant disease (primary PFI >3 mos) • Prior bevacizumab allowed* • Prior PARPi allowed • Patients with BRCA mutations allowed Mirvetuximab PHASE 3 RANDOMIZED TRIAL FOR MIRVETUXIMAB USING PS2+ SCORING IN
Slide 13: Mirvetuximab Combinations and Label Expansion
13 PLATINUM-RESISTANTPLATINUM-SENSITIVE MIRVETUXIMAB + BEVACIZUMAB1 Median Number of Prior Therapies (Range): 3 (1-8) MIRVETUXIMAB + CARBOPLATIN2 Median Number of Prior Therapies (Range): 2.5 (1-6) FRα-HIGH1 (n=28) AURELIA-TYPE (n=16) FRα-MED + FRα-HIGH1 (n=10) 39% ORR 56% ORR 80% ORR 7.1 mos mPFS 9
Slide 14: 2020 Drug Treatable Recurrent Ovarian Cancer Patients
14 2020 DRUG TREATABLE RECURRENT OVARIAN CANCER PATIENTS 2L 3L PLANTINUM - RESISTANT 10k PLANTINUM - SENSITIVE 2k 2L 3L 4L 2L 3L 5k 9k 8k ~50% SINGLE AGENT CHEMO ~50% SINGLE AGENT CHEMO *Numbers represent Company estimates of US patients with conditions covered by the Company’s targeted indications.
Slide 15: Mirvetuximab Market Opportunity
15 MIRVETUXIMAB MARKET OPPORTUNITY FIRST TARGETED INDICATION AND ADDITIONAL EXPANSION INDICATIONS WOULD ADDRESS KEY SEGMENTS OF RECURRENT OVARIAN CANCER MARKET 2L 3L PLANTINUM - RESISTANT 10k PLANTINUM - SENSITIVE 2k 2L 3L 4L 2L 3L 5k 9k 8k FIRST TARGETED INDICATION: MONOTHERAPY 2L- 4L PLATINUM -RES
Slide 16: Mirvetuximab Program Summary
16 ROBUST DATA • Strong and consistent efficacy signals observed in FRα-high patients • Favorable tolerability • PS2+ reliably identified patients most likely to benefit SORAYA: POTENTIAL PATH TO ACCELERATED APPROVAL • Enroll first patient in Q1 2020 • Topline data expected in mid-2021; BLA expected
Slide 17: Someone you know has been diagnosed with AML
17 • More than 10,000 deaths due to AML in US each year1 • 5-year overall survival is ~25%1 • Median overall survival is ~6 months in relapsed/refractory AML2-3 C H E M O + TARGETED THERAPY STEM CELL TRANSPLANT DIAGNOSIS ~ 21,500 NEW CASES DIAGNOSEDANNUALLY 1 CHEMOTHERAPY U R G E N T NEED SELECT CAS
Slide 18: IMGN632
I M G N 6 3 2 18 DESIGNED TO TARGET MULTIPLE CD123+ HEMATOLOGIC MALIGNANCIES KEY ATTRIBUTES • CD123-targeted ADC with novel DNA-acting payload • Demonstrated activity with complete responses in AML and BPDCN1 • Favorable safety observed at multiple dose levels1 DEVELOPMENT STRATEGY • Fast-to-market
Slide 19: IMGN632 Advancing Expansion Cohorts
19 I M G N 6 3 2 ADVANCING EXPANSION COHORTS • Recommended Phase 2 dose and schedule identified • Monotherapy and combination trials enrolling – Monotherapy: BPDCN and frontline MRD+ AML – Doublet: with azacitidine and with venetoclax in r/r AML – Triplet: with azacitidine and venetoclax in AML • Ex
Slide 20: Select Portfolio of Early Stage Product Candidates
20 ADVANCING A SELECT PORTFOLIO OF EARLY STAGE PRODUCT CANDIDATES • First-in-class ADAM9-targeting therapy • ADAM9 is overexpressed in multiple solid tumors (e.g., NSCLC, gastric, pancreatic, TNBC) 1 • Comprised of high-affinity humanized antibody with YTE mutation conjugated to DM21, a next-generat
Slide 21: Evolving Our Approach to Partnering
EVOLVING OUR APPROACH TO PARTNERING CO- OWNERSHIP AND MONETIZATION OF ASSETS TO STRENGTHEN BALANCE SHEET 21 LEGACY PLATFORM DEALS
Slide 22: The Next Months: Our Path to Success
22 THE NEXT 12 MONTHS OUR PATH TO SUCCESS MIRVETUXIMAB SORAVTANSINE • Open pivotal SORAYA trial in Q1 2020 • Enroll patients in confirmatory MIRASOL trial • Initiate additional platinum-sensitive combination in early 2020 • Present initial data from FORWARD II platinum-agnostic and updated triplet c
Slide 23: Robust Data in Lead Mirvetuximab Program
ROBUST DATA IN LEAD MIRVETUXIMAB PROGRAM ACCELERATED PATH TO PIVOTAL DATA IN 2021 AND POTENTIAL APPROVAL IN 2022 IMGN632 ADVANCING INTO EXPANSION DIVERSE PORTFOLIO OF EARLY STAGE PRODUCT CANDIDATES STRONG CASH POSITION ANTICIPATED COMPENDIA LISTING FOR FOLLOW - O N INDICATIONS BEGINNING IN 2022